AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16552194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 16552194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergel treatment
Number of subjects: 32
Study 16552194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 14651424 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation (IF)
Number of subjects: 110
Study 14651424 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 110
Study 14651424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EQ‐5D and SF‐36
Number of subjects: 110
Study 10961223 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-fluoroscopy
Number of subjects: 78
Study 10961223 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 78
Study 9069663 — intervention group
Group type: EXPERIMENTAL
Intervention: Written cognitive pretraining
Number of subjects: 0
Study 9069663 — intervention group
Group type: COMPARATOR
Intervention: General group information (Control)
Number of subjects: 0
Study 8101302 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid plus vitamin B6
Number of subjects: 118
Study 8101302 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 alone
Number of subjects: 118
Study 3550556 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone
Number of subjects: 422
Study 3550556 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and endocrine therapy
Number of subjects: 422
Study 31250134 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 323
Study 29750664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program (CPSMP)
Number of subjects: 424
Study 27613076 — intervention group
Group type: EXPERIMENTAL
Intervention: DFN-02 (10 mg sumatriptan plus 0.20% DDM)
Number of subjects: 96
Study 27613076 — intervention group
Group type: COMPARATOR
Intervention: Commercially available intranasal sumatriptan 20 mg
Number of subjects: 96
Study 27613076 — intervention group
Group type: COMPARATOR
Intervention: 4 mg subcutaneous sumatriptan
Number of subjects: 96
Study 27613076 — intervention group
Group type: COMPARATOR
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 96
Study 24165272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 133
Study 24165272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg/day
Number of subjects: 133
Study 24165272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin and tadalafil
Number of subjects: 133
Study 23079535 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz at 80% of rest motor threshold)
Number of subjects: 38
Study 23079535 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 38
Study 20042256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate powder (once-daily)
Number of subjects: 100
Study 20042256 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride tablets (thrice-daily)
Number of subjects: 100
Study 18946458 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/day for adults, 400 IU/day for children) for 60 days
Number of subjects: 102
Study 18946458 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 102
Study 18946458 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 102
Study 15663589 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day oral tibolone
Number of subjects: 70
Study 15663589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12673143 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 10
Study 12673143 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 microg)
Number of subjects: 10
Study 12673143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11004258 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing of the nasolacrimal system under general anesthesia
Number of subjects: 60
Study 8842828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan Communication System (DanCS) boards
Number of subjects: 30
Study 8471375 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 24
Study 8471375 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg kg‐1
Number of subjects: 24
Study 8471375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 3519225 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose furosemide (120 mg i.v. during the initial 24 hours)
Number of subjects: 73
Study 3519225 — intervention group
Group type: COMPARATOR
Intervention: Low dose furosemide (20 mg i.v. during the initial 24 hours)
Number of subjects: 73
Study 30899230 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative program consisting of education strategies, direct and indirect contact with people diagnosed with SMD, and skill development, delivered over six face-to-face sessions and two additional sessions with healthcare center directors.
Number of subjects: 210
Study 30899230 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 210
Study 30275282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 2476
Study 30275282 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2476
Study 30275282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2476
Study 27130973 — intervention group
Group type: COMPARATOR
Intervention: 16 Gy radiation (Oraya, OT)
Number of subjects: 0
Study 27130973 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-VEGF therapy
Number of subjects: 0
Study 24351072 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of myo-inositol/die plus 400 mcg of folic acid/die orally for six months
Number of subjects: 50
Study 24351072 — intervention group
Group type: COMPARATOR
Intervention: 1 g of D-chiro-inositol/die plus 400 mcg of folic acid/die orally for six months
Number of subjects: 50
Study 22414875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone administration
Number of subjects: 0
Study 22414875 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19523875 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1000 mg/day for 12 weeks)
Number of subjects: 40
Study 19523875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no omega-3 supplementation)
Number of subjects: 40
Study 19523875 — intervention group
Group type: COMPARATOR
Intervention: Active control (exercise training without omega-3)
Number of subjects: 40
Study 19523875 — intervention group
Group type: COMPARATOR
Intervention: Inactive control (no exercise training)
Number of subjects: 40
Study 18569546 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded parallel squats followed by countermovement jumps
Number of subjects: 8
Study 18569546 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement jumps followed by loaded parallel squats
Number of subjects: 8
Study 18569546 — intervention group
Group type: COMPARATOR
Intervention: Countermovement jumps
Number of subjects: 8
Study 15831642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy (CRT)
Number of subjects: 124
Study 15831642 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group A)
Number of subjects: 193
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mcg of consensus interferon plus ribavirin (1000/1200 mg/daily) for 24 weeks (group B)
Number of subjects: 193
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mcg of consensus interferon plus ribavirin for 48 weeks (group C)
Number of subjects: 193
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mcg of consensus interferon plus ribavirin for 48 weeks (group D)
Number of subjects: 193
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sustained response in patients with genotype 2/3
Number of subjects: 193
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sustained response in patients with genotype 1
Number of subjects: 193
Study 14568269 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mcg of consensus interferon plus ribavirin for 48 weeks in naive genotype 1 patients
Number of subjects: 193
Study 10591300 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial sanctions for failing to verify vaccinations (experimental group)
Number of subjects: 911
Study 10591300 — intervention group
Group type: COMPARATOR
Intervention: No financial sanctions (control group)
Number of subjects: 911
Study 8982555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α-hydroxycalciferol (1α[OH]D3) at a low dose (0.25 μg/day, n = 56, Group L)
Number of subjects: 165
Study 8982555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α-hydroxycalciferol (1α[OH]D3) at a higher dose (0.5 to 1.0 μg/day, average 0.58 ± 0.02 μg/day, n = 65, Group H)
Number of subjects: 165
Study 8982555 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 44, Group N)
Number of subjects: 165
Study 8982555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α-hydroxycalciferol (1α[OH]D3)
Number of subjects: 165
Study 1680275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (4 mg)
Number of subjects: 0
Study 1680275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6195238 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Exhaust Suit (TBE-suit)
Number of subjects: 64
Study 6195238 — intervention group
Group type: COMPARATOR
Intervention: Conventional Theatre Clothing (C-clothing)
Number of subjects: 64
Study 31539378 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 36
Study 31539378 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 36
Study 30075553 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) plus carbamazepine
Number of subjects: 54
Study 30075553 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine only (Control)
Number of subjects: 54
Study 26481591 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (non-ionic IOCM)
Number of subjects: 146
Study 26481591 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (ionic LOCM)
Number of subjects: 146
Study 23802779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant language prime
Number of subjects: 21
Study 22664561 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training curriculum for colonoscopy
Number of subjects: 50
Study 20397856 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16
Study 20397856 — intervention group
Group type: COMPARATOR
Intervention: Traditional progressive resistance exercise (TPRE)
Number of subjects: 16
Study 18043492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone in decreasing doses
Number of subjects: 102
Study 18043492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18043492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 102
Study 15715190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam plus nebulised Lignocaine
Number of subjects: 50
Study 15715190 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alfentanyl
Number of subjects: 50
Study 12082590 — intervention group
Group type: EXPERIMENTAL
Intervention: GPIIb/IIIa antagonist orbofiban
Number of subjects: 924
Study 10233322 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil (500 mg daily)
Number of subjects: 160
Study 10233322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bland lipid miglyol)
Number of subjects: 160
Study 7595759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) 2 mg/m2/d, days 1, 2; Etoposide 200-300 mg/m2/d, days 1-3; G-CSF 5-10 micrograms/d subcutaneously, days 4-18, every 4 weeks
Number of subjects: 9
Study 7595759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) and Etoposide with G-CSF
Number of subjects: 9
Study 2185680 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenofemoral flush ligation and multiple lower leg avulsions with leg exsanguinated with a Rhys‐Davies cuff and ischaemia maintained with a pneumatic tourniquet
Number of subjects: 100
Study 2185680 — intervention group
Group type: COMPARATOR
Intervention: Identical surgery with a 30 degree head down tilt only
Number of subjects: 100
Study 7319134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 0
Study 7319134 — intervention group
Group type: COMPARATOR
Intervention: Oral dihydrocodeine (60 mg)
Number of subjects: 0
Study 31655984 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 55
Study 31655984 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 55
Study 27488754 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced heart failure education with a 6-month telephone follow-up program (EHFP)
Number of subjects: 248
Study 27488754 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 248
Study 25872504 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with radiographs at 1, 2, 6, and 12 weeks post-trauma
Number of subjects: 697
Study 25872504 — intervention group
Group type: COMPARATOR
Intervention: Radiographs beyond the initial follow-up only when clinically indicated
Number of subjects: 697
Study 25872504 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 697
Study 24225081 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (20 grams twice a day)
Number of subjects: 250
Study 24225081 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 250
Study 24225081 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 250
Study 24225081 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including protein supplementation, isocaloric placebo, and no supplementation)
Number of subjects: 250
Study 21273606 — intervention group
Group type: EXPERIMENTAL
Intervention: Saracatinib (175 mg daily, orally or via gastrostomy tube)
Number of subjects: 9
Study 19470385 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rapamycin
Number of subjects: 60
Study 19470385 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rapamycin
Number of subjects: 60
Study 19470385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17943687 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive enhancement therapy (NET) + Work therapy (WT)
Number of subjects: 145
Study 17943687 — intervention group
Group type: COMPARATOR
Intervention: Work therapy (WT) alone
Number of subjects: 145
Study 15283871 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening
Number of subjects: 10000
Study 15283871 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening
Number of subjects: 10000
Study 15283871 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice (Control)
Number of subjects: 10000
Study 11483228 — intervention group
Group type: EXPERIMENTAL
Intervention: Extend Bar (30 g total carbohydrate, including 5 g uncooked cornstarch, 3 g protein, 3 g fat)
Number of subjects: 28
Study 11483228 — intervention group
Group type: COMPARATOR
Intervention: Placebo Bar (30 g total carbohydrate, 3 g protein, 3 g fat)
Number of subjects: 28
Study 9489591 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg orally) with food
Number of subjects: 12
Study 9489591 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg orally) after food
Number of subjects: 12
Study 9489591 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone (400 mg orally) fasting
Number of subjects: 12
Study 7826783 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified gas
Number of subjects: 41
Study 7826783 — intervention group
Group type: COMPARATOR
Intervention: Non-humidified gas
Number of subjects: 41
Study 3057688 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza) conversion from cyclosporine (CsA)
Number of subjects: 66
Study 3057688 — intervention group
Group type: COMPARATOR
Intervention: Continuous cyclosporine (CsA) therapy
Number of subjects: 66
Study 31797160 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure in new patient visits
Number of subjects: 168
Study 31797160 — intervention group
Group type: EXPERIMENTAL
Intervention: Time pressure in follow-up visits
Number of subjects: 168
Study 31797160 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplaces with values alignment and emphasis on quality
Number of subjects: 168
Study 29316885 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly cash transfer (unconditional)
Number of subjects: 120
Study 29316885 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer on school attendance
Number of subjects: 120
Study 29316885 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-off payment conditional on a clinic visit
Number of subjects: 120
Study 29316885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfers (CTs)
Number of subjects: 120
Study 28843616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (2.403 mg/daily) for one year
Number of subjects: 43
Study 26849930 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroButton
Number of subjects: 97
Study 26849930 — intervention group
Group type: COMPARATOR
Intervention: Interference Screw
Number of subjects: 97
Study 23278858 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based severity index
Number of subjects: 173
Study 21244862 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based dietary-behavioral-physical activity intervention
Number of subjects: 376
Study 21244862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 376
Study 18058036 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Integration Survey (SIS)
Number of subjects: 129
Study 17634167 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched meat (WM)
Number of subjects: 22
Study 17634167 — intervention group
Group type: COMPARATOR
Intervention: Control meat (CM)
Number of subjects: 22
Study 15477286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 61)
Number of subjects: 116
Study 15477286 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 55)
Number of subjects: 116
Study 11529540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose erythromycin (2.5 mg kg(‐1) per dose 6 hourly)
Number of subjects: 43
Study 11529540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9764584 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous mutation in the ATM gene (insertion A at NT 898)
Number of subjects: 80
Study 9764584 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no mutations detected)
Number of subjects: 80
Study 9764584 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated percentage of AT heterozygous patients in radiosensitive cases
Number of subjects: 80
Study 9764584 — intervention group
Group type: COMPARATOR
Intervention: Estimated percentage of AT heterozygous patients in control subjects
Number of subjects: 80
Study 7639372 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil (20 micrograms/kg)
Number of subjects: 30
Study 7639372 — intervention group
Group type: COMPARATOR
Intervention: methohexital (0.5 mg/kg)
Number of subjects: 30
Study 3146231 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 0
Study 3146231 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 0
Study 3146231 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 3146231 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with enflurane/alfentanil
Number of subjects: 0
Study 3146231 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane with premedication (flunitrazepam and atropine, combined with 70% N2O/30% O2)
Number of subjects: 0
Study 29793467 — intervention group
Group type: EXPERIMENTAL
Intervention: MINISTOP intervention
Number of subjects: 315
Study 29793467 — intervention group
Group type: COMPARATOR
Intervention: Basic pamphlet on dietary and physical activity behaviors (control group)
Number of subjects: 315
Study 26695077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis with a Vitamin E (VE)‐coated dialysis membrane for 12 months
Number of subjects: 260
Study 26695077 — intervention group
Group type: COMPARATOR
Intervention: Non‐VE coated equivalent dialysis for 12 months
Number of subjects: 260
Study 26695077 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C3 levels
Number of subjects: 260
Study 26695077 — intervention group
Group type: EXPERIMENTAL
Intervention: SC5b‐9 levels
Number of subjects: 260
Study 25500372 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with high sodium
Number of subjects: 390
Study 25500372 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with intermediate sodium
Number of subjects: 390
Study 25500372 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with low sodium
Number of subjects: 390
Study 25500372 — intervention group
Group type: COMPARATOR
Intervention: Control diet with low sodium
Number of subjects: 390
Study 22722359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sign-out checklist with faculty member review and feedback
Number of subjects: 0
Study 22722359 — intervention group
Group type: COMPARATOR
Intervention: Standard sign-out instruction
Number of subjects: 0
Study 20478739 — intervention group
Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for thermal cold perception thresholds (CT)
Number of subjects: 38
Study 20478739 — intervention group
Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for thermal warm perception thresholds (WT)
Number of subjects: 38